StockData
Braveheart Bio, Inc. logo

Braveheart Bio, Inc. (BRVE) stock

BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$18.78−0.71 (-3.64%)

Close on Nov 17, 2026Market cap $1.69BP/E –Yield –

Braveheart Bio cash

Cash and short-term investments held at the end of each period.

Braveheart Bio's cash was $503.50M at Sep 30, 2026. For fiscal 2025 it was $89.16M.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$89.16M–
FY2024Dec 31, 2024$0–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$503.50M+25174900.0%
Q2 FY2026Jun 30, 2026$122.83M–
Q4 FY2025Dec 31, 2025$89.16M–
Q3 FY2025Sep 30, 2025$67.53M–
Q2 FY2025Jun 30, 2025$2.00K–
Q4 FY2024Dec 31, 2024$0–

More Braveheart Bio figures

See a number that looks wrong?